HBMN:SWX
HBM Healthcare Investments AG
235,00 CHF
arrow_upward
+1,29%(+3,00) 1 d
30 apr., 17:31:54 GMT+2 · CHF
search
Alla symboler
1 d
5 d
1 m
6 m
Hittills i år
1 år
5 år
MAX
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för HBMN …
Öppen
231,50 CHF
Högt
235,00 CHF
Lågt
228,00 CHF
Börsvärde
1,58 md
Genomsn. vol.
6,38 tn
Volym
2,81 tn
Utdelning
3,19 %
Kvartalsvis utdelning
1,88 CHF
Ex-utdelningsdatum
2 juli 2025
P/E-tal
6,54
52v högst
245,50 CHF
52v lägst
157,40 CHF
EPS
35,93 CHF
Utestående aktier
6,74 mn
Nyheter och artiklar
Från källor på webben
Vietnam.vn
·
för 23 minuter sedan
S&P 500 och Nasdaq noterade sina starkaste månatliga uppgångar sedan 2020.
Yahoo Finance
·
för 30 minuter sedan
Assessing Sivers Semiconductors (OM:SIVE) Valuation After Annual Report Delay And Nasdaq Dual Listing Preparations
Moomoo
·
för 30 minuter sedan
Dow Jones Top Markets Headlines at 11 PM ET: Investors Ride Google, Caterpillar to Market's Best Month Since 2020 | Wheat ...
Folkbladet
·
för 38 minuter sedan
Nikkei följer Wall Streets fotspår uppåt
Profil
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Om HBM Healthcare Investments AG
AI-innehåll kan innehålla fel. Läs mer